会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明公开
    • 세포를 이용한 항염증 또는 항암 조절제의 탐색방법
    • 抗炎剂控制剂或抗癌剂控制剂的筛选方法
    • KR1020010002084A
    • 2001-01-05
    • KR1019990021694
    • 1999-06-11
    • 한국생명공학연구원
    • 윤도영조영식조경주정안식김보연디나렐로찰스박순희
    • C12Q1/00
    • PURPOSE: A screening method of anti-inflammatory control agent or anti-cancer control agent is provided, which develops new remedial agents against degenerative brain disease, senile disease, chronic disease, cancer and the like. CONSTITUTION: A screening method of anti-inflammatory control agent or anti-cancer control agent is characterized by screening controlling material of inflammation induction factor selected from the group of interleukin-1, interleukin-1 beta converting enzyme, interleukin-18 by detecting proliferation of T-helper cell which is induced specifically by interleukin-1. The T-helper cell is characterized by D10S cell. The controlling material of inflammation induction factor is characterized by activity repressor which represses interleukin-1 or blocks signal transfer by interleukin-1. The controlling material of inflammation induction factor is characterized by activity promoter or activity repressor of interleukin-1 beta converting enzyme.
    • 目的:提供抗炎控制剂或抗癌药物的筛选方法,开发抗退行性脑病,老年病,慢性病,癌症等新辅助药物。 构成:抗炎控制剂或抗癌药物的筛选方法的特征在于筛选选自白细胞介素-1,白细胞介素-1β转换酶,白细胞介素-18的炎症诱导因子的物质, 由白介素-1特异性诱导的T辅助细胞。 T辅助细胞的特征在于D10S细胞。 炎症诱导因子的控制材料的特征在于抑制白细胞介素-1或通过白介素-1抑制信号转导的活性抑制因子。 炎症诱导因子的控制材料以白细胞介素-1β转换酶的活性启动子或活性阻遏物为特征。
    • 4. 发明公开
    • 인간 파필로마바이러스에 대한 백신용 벡터 및 그에 의해형질전환된 미생물
    • 用于抗HPV(人造血管病毒)疫苗和转化的微生物的载体
    • KR1020040034511A
    • 2004-04-28
    • KR1020030072407
    • 2003-10-17
    • 주식회사 바이오리더스한국생명공학연구원
    • 성문희부하령이종수정창민홍승표김철중박순희표현미
    • C12N15/86
    • C07K14/005A61K39/0011A61K2039/523C12N7/00C12N2710/20022C12N2730/10122C12N2830/008
    • PURPOSE: A vector for anti-HPV(human Papillomavirus) vaccine and a transformed microorganism therewith are provided, thereby expressing capsid L1 protein of human Papillomavirus on the surface of the microorganism, so that the transformed microorganism can be useful for prevention and treatment of hPV. CONSTITUTION: A vector for anti-HPV(human Papillomavirus) vaccine contains one or two gene selected from pgsB, pgsC and pgsA encoding polygammaglutamic acid synthase complex and an antigen protein gene of human Papillomavirus, wherein the antigen protein gene is one or two surface antigen protein gene selected from HPV capsid L1 and L2 or one or two antigen protein gene selected from HPV E6 and E7. The transformed microorganism with the vector for anti-HPV(human Papillomavirus) vaccine is provided, wherein the microorganism is selected from Escherichia coli, Salmonella typhi, Salmonella typhimurium, Vibrio cholera, Mycobacterium bovis, Shigella, Bacillus, Lactobacillus, Lactococcus, Staphylococcus, Listeria monocytogenes and Streptococcus.
    • 目的:提供用于抗HPV(人乳头瘤病毒)疫苗和转化的微生物的载体,从而在微生物表面上表达人乳头瘤病毒的衣壳L1蛋白,从而转化的微生物可用于预防和治疗hPV 。 构成:用于抗HPV(人乳头瘤病毒)疫苗的载体含有选自编码聚氨基葡萄酸合酶的pgsB,pgsC和pgsA的一个或两个基因和人乳头瘤病毒的抗原蛋白基因,其中抗原蛋白基因是一个或两个表面抗原 选自HPV衣壳L1和L2的蛋白质基因或选自HPV E6和E7的一个或两个抗原蛋白基因。 提供了具有抗HPV(人乳头瘤病毒)疫苗载体的转化微生物,其中微生物选自大肠杆菌,伤寒沙门氏菌,鼠伤寒沙门氏菌,霍乱弧菌,牛分枝杆菌,志贺氏菌,芽孢杆菌,乳杆菌属,乳球菌属,葡萄球菌属,李斯特菌 单核细胞增多和链球菌。